Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Despite the low percentage, SCLC causes about 250,000 deaths worldwide annually. "The really sad thing about it, and why we wanted to look at small-cell lung cancer, is that the average survival ...

If certain proteins attach to PD-1 receptors, this causes immune cells to stop ... found Opdivo to be effective for treating non-small cell lung cancer (NSCLC) in adults. One trial found that ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

The Small Cell Lung Cancer market growth is driven by factors like increase in the prevalence of Small Cell Lung Cancer, investments in research and development, entry of emerging therapies during ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...